Drug Trial Radar · NCT07908654
A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
25,000
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Sep 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Guangzhou Patronus Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, observer-blinded, placebo-controlled Phase III clinical trial to evaluate efficacy, immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.
Conditions
- Respiratory Syncytial Virus (RSV)
- Respiratory Syncytial Virus (RSV) Infection
- RSV Vaccine
Interventions
LYB005Biological
0.5 mL per dose.
PlaceboBiological
0.5 mL 0.9% sodium chloride (normal saline) injection per dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) from 14 days post-vaccination through the end of the first RSV seasonTime frame: From 14 days post-vaccination through the end of the first RSV season
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.